Novacyt: litigation settlement weighs on share price
The Franco-British diagnostics group says it has reached a commercial settlement that puts an end to all complaints and claims brought by the government in proceedings before the High Court of Justice.
In 2022, the DHSC had lodged a claim against Novacyt in a contractual dispute concerning a supply contract for rapid tests against Covid.
The trial which was due to start this week will therefore not take place.
In a press release, Novacyt stresses that neither party has admitted any liability or wrongdoing in the case.
Following these announcements, the share price was down by more than 16% at around 11:40 am.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction